Trial Profile
Safety study of Recombinant human C1-INH (rhC1-INH) in pregnant women with hereditary angioedema (HAE )
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Mar 2018
Price :
$35
*
At a glance
- Drugs Conestat alfa (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; Therapeutic Use
- 26 Mar 2018 New trial record
- 05 Mar 2018 Results assessing safety of rhC1-INH in pregnant women with HAE, presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology